The novel oral anticoagulants

  • C. R
  • D. G
  • Rojas-Hernandez C
 et al. 
  • 1

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

After the introduction of warfarin, long-term oral anticoagulation treatment remained unchanged for more than 50 years. Most recently, with the development and approval of new oral anticoagulants, the treatment of medical conditions that require thrombosis prophylaxis and long-term anticoagulation has become more complex. In the case of venous thromboembolism (VTE) prevention after orthopedic surgery, the new oral agents will be less costly than the parenteral alternative. In other settings (such as atrial fibrillation or treatment of acute VTE), the new agents will offer additional convenience at higher cost, but the degree to which they will reduce clinically important events such as thrombosis or bleeding will be limited, especially for patients on optimally controlled warfarin. As the use of the new oral anticoagulants becomes more widespread, it will be important for all clinicians to have a basic understanding of their pharmacology, advantages, and limitations. Although the need to measure or reverse the effect of these drugs will arise infrequently, clinicians--especially hematologists--will desire evidence-based recommendations about how to manage such scenarios, which will require research studies.

Author-supplied keywords

  • Administration
  • Anticoagulants/*administration & dosage
  • Benzimidazoles/administration & dosage
  • Dabigatran
  • Humans
  • Morpholines/administration & dosage
  • Oral
  • Pyrazoles/administration & dosage
  • Pyridones/administration & dosage
  • Rivaroxaban
  • Thiophenes/administration & dosage
  • Venous Thromboembolism/prevention & control
  • acetylsalicylic acid
  • acute coronary syndrome
  • anticoagulant agent
  • anticoagulant therapy
  • apixaban
  • article
  • aspirin
  • atecegatran metoxil
  • atrial fibrillation
  • azd 0837
  • beta-Alanine/administration & dosage/analogs & der
  • betrixaban
  • blood clotting time
  • brain hemorrhage
  • brain ischemia
  • cerebrovascular accident
  • clopidogrel
  • cost control
  • dabigatran
  • dabigatran etexilate
  • darexaban
  • drug approval
  • drug blood level
  • drug determination
  • drug effect
  • drug efficacy
  • drug half life
  • drug safety
  • edoxaban
  • enoxaparin
  • eribaxaban
  • evidence based practice
  • fondaparinux
  • health care cost
  • heart infarction
  • heart valve replacement
  • hematologist
  • hemodialysis
  • human
  • international normalized ratio
  • kidney failure
  • lactation
  • letaxaban
  • low molecular weight heparin
  • ly 517717
  • n [2 [4 (1 methyl 4 piperidinyl) 1 piperazinyl] 2
  • orthopedic surgery
  • partial thromboplastin time
  • priority journal
  • rivaroxaban
  • thrombin time
  • thrombosis prevention
  • ticlopidine
  • ttp 889
  • unclassified drug
  • venous thromboembolism
  • warfarin

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • Rojas-Hernandez C.

  • Garcia D.

  • C M Rojas-Hernandez

  • D A Garcia

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free